Datopotamab deruxtecan has received Breakthrough Therapy Designation from the U.S. FDA for treating patients with advanced EGFR-mutated non-small cell lung cancer after prior treatments. This designation aims to expedite the development process for this promising therapy.
Company Information
Company
Daiichi Sankyo
Location
Munich, Bavaria, Germany
About
Daiichi Sankyo is a global pharmaceutical company that focuses on innovative and sustainable practices in the development of medicines. The company aims to contribute to the health of patients through its wide-ranging drug development portfolio, particularly in oncology. Additionally, AstraZeneca is a biopharmaceutical company that specializes in the development of medicines for various diseases, with a strong emphasis on oncology research. Both companies are working together to advance treatments for serious medical conditions.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Daiichi Sankyo ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.